Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Brief Summary: This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based chemotherapy or 3rd relapse.


Options:
A: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab
B: Arm Label: Arm A: Chemotherapy + Bevacizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Chemotherapy, Drug: Placebos | Arm Label: Arm B: Chemotherapy + Bevacizumab + Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Atezolizumab, Drug: Chemotherapy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo
C: Arm Label: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Arm Label: Olaparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib, Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Olaparib and Cediranib
D: Arm Label: Standard treatment; Type: OTHER; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Arm Label: Carboplatin + Paclitaxel + Bevacizumab + Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Rucaparib | Arm Label: Carboplatin + Paclitaxel + Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Rucaparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib

Answer: B